SASergey O. Ayvasyan

Sergey O. Ayvasyan

*This is an algorithmically generated author record based on publicly available information.

Sergey O. Ayvasyan has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ketogenic diet in the treatment of drug-resistant epilepsy in children: Assessment of clinical efficacy, health care resource consumption, and direct medical costs

    by E.G. Lukyanova, A.G. Tolkushin, S.O. Ayvazyan, K.V. Osipova, E.A. Pyrieva, A.I. Krapivkin, V.A. Zhestkov

    Objective. To evaluate the impact of the ketogenic diet (KD) on clinical outcomes, health resource consumption, including medication burden, hospitalization rates, and outpatient care, and direct medical costs (DMCs) in pediatric patients with drug-resistant epilepsy (DRE). Material and methods. A retrospective, non-interventional observational study was conducted at a specialized medical center. Data were collected from 58 children diagnosed with DRE: 29 patients received the ketogenic diet, while 29 patients comprised the comparison group. The clinical characteristics of epilepsy, frequency of seizures, efficacy of treatment, duration of the ketogenic diet, occurrence of adverse events, history of drug therapy, and the number of hospitalizations and outpatient consultations with a neurologist over two years were systematically evaluated. Based on the data obtained, the DMCs were calculated over 10 years. Results. The administration of the KD resulted in an average reduction of 83% in the number of epileptic seizures as compared to baseline (p=0.037) and a 78% decrease relative to the comparison group (p=0.013). The mean number of hospitalizations over two years was significantly lower in the KD group, with 2.70±3.22 hospitalizations compared to 10.14±7.79 in the comparison group (p=0.0001). Additionally, the number of consultations with a neurologist was markedly reduced (p=0.00001). By decreasing the consumption of health care resources — specifically, hospitalizations and outpatient neurological consultations — the DMCs over a ten-year horizon, excluding the cost of the ketogenic diet, were 3.05 times lower when utilizing the ketogenic diet; while maintaining observed trends in clinical efficacy, and taking into account the cost of the ketogenic diet, DMCs were reduced by approximately 130.000 rubles. The cost of antiepileptic medications accounted for a smaller share of DMCs, contributing 15% to overall expenditure. Conclusions. The application of the KD in children with DRE yielded favorable clinical outcomes, characterized by a significant reduction in seizure frequency, decreased consumption of health care resources, and financial savings on DMCs. These findings support the consideration of the KD as a clinically effective and cost-effective treatment approach compared to standard management practices for patients not receiving the KD.

  • Open Access

    Ketogenic diet using medical nutrition in infants: the experience of a Russian center

    by E. G. Luk`yanova, S. O. Ayvazyan, K. V. Osipova, E. A. Pyrieva, A. I. Krapivkin, Е. Г. Лукьянова, С. О. Айвазян, К. В. Осипова, Е. A. Пырьева, А. И. Крапивкин

    Background. The aim of this study is to evaluate the efficacy and safety of initiating a classical ketogenic diet in infants with epileptic encephalopathies using the specialized formula. Materials and methods. A single-center prospective observational study included 14 infants with drug-resistant epileptic seizures. A genetic etiology was confirmed in 9 patients, including 2 children with glucose transporter 1 deficiency syndrome. The ketogenic diet was initiated in a hospital setting with gradual replacement of feedings with a specialized ketogenic formula used off-label outside the approved age. The dietary energy value and the ketogenic ratio were tailored individually. The follow-up period was 6 to 12 months. Changes in seizure frequency, diet tolerability, blood ketone levels, acid-base status, and physical development of the children were evaluated. Results. Seizure freedom was achieved in 2 children with GLUT1 syndrome (14.3 %). A 75-99% reduction in seizure frequency was observed in 4 patients (28.6%), and a 50-74% decrease in 6 children (42.9%). Two patients (14.3%) demonstrated a reduction in seizure frequency of less than 50%. Thus, a clinically meaningful response, defined as a reduction in seizure frequency of at least 50%, was achieved in 12 out of 14 children (85.7%). No serious adverse events or diet discontinuation due to intolerance were reported. Some patients developed transient metabolic acidosis, which resolved following ketogenic ratio adjustment and anticonvulsant therapy modification. No negative trends in physical development were observed. Conclusion. Early initiation of a ketogenic diet in infants with epileptic encephalopathies was associated with a significant reduction in seizure frequency and satisfactory tolerability. The use of specialized nutrition support facilitates adherence to the calculated ketogenic ratio and dietary management in infants. Safe implementation of nutrition therapy requires an inpatient initiation, individualized nutritional formulas, and routine clinical and laboratory monitoring.

  • Classification, diagnosis and therapy of attention deficit hyperactivity disorder

    by V.P. Zykov, I.B. Komarova, E.B. Novikova, S.O. Ayvazyan

    The literature review analyzes modern concepts of attention deficit hyperactivity disorder (ADHD), the relevance of timely detection of the disease. A working classification is presented, dominant comorbid syndromes, anxiety, sleep disorders, autism are described. The possibilities of detecting the disease through parent-teacher questionnaires are considered. Age-related features of ADHD, gender differences are noted, the results of short-term and long-term courses of atomoxetine use are summarized, the results of randomized studies on the positive effect of the drug on the socialization of patients, academic performance and the possibility of correcting comorbid anxiety syndromes, autistic disorders and syncopal states are presented. In domestic practice of ADHD therapy, Atomoxetine it is a first-line drug.


  • Modern approaches to the diagnosis and treatment of Dravet syndrome in the Russian Federation. (Literature review and resolution of the Expert Council)

    by V.I. Guzeva, S.I. Kutsev, A.S. Petrukhin, S.O. Ayvazyan, E.D. Belousova, S.G. Burd, I.V. Volkov, O.V. Globa, M.YU. Dorofeeva, N.A. Ermolenko, et al.

    Dravet syndrome (DS) is a rare genetic disorder with onset at 1 year of age, one of the most severe forms of epilepsy, which is characterized by a high frequency and severity of seizures, impaired psychoneurological development, disability and high mortality. Timely diagnosis and treatment can significantly alleviate the course of DS and improve the quality of life of patients and their families. Currently, there is an urgent need to increase awareness of pediatric neurologists and primary care physicians about the diagnostic criteria for the timely detection of patients with DS, referral to an epileptologist to confirm the diagnosis and prescribe the necessary therapy. The provisions of the Expert Council’s resolution, which took place on March 14, 2025, are presented.


  • Open Access

    Whole-exome sequencing is the molecular-genetic test of the first-line in developmental and epileptic encephalopathies

    by Татьяна Викторовна Кожанова, Светлана Сергеевна Жилина, Tatyana I. Meshcheryakova, Александр Андреевич Абрамов, Sergey O. Ayvasyan, Николай Николаевич Заваденко, Татьяна Ивановна Мещерякова, Сергей Оганесович Айвазян

    Introduction. Developmental and epileptic encephalopathy are severe developmental disorders of the nervous system, characterized by recurrent epileptic seizures that begin over the neonatal period or childhood, accompanied by psychomotor retardation and intellectual disability. Massively parallel sequencing is a technology used to determine the complete nucleotide sequence of DNA or RNA. The technology is characterized by the high productivity and speed, marking the beginning of the golden age of genetics, allowing large volumes of DNA to be sequenced quickly and efficiently at lower costs. The aim of this study is to evaluate the effectiveness of whole- exome sequencing as a first-line genetic test in patients with developmental and epileptic encephalopathy and detect the structure of identified variants in the Russian population. Materials and methods. Patients with drug-resistant seizures, onset in neonatal and early childhood, hospitalized in the Psychoneurological Department during 2017–2023. All patients underwent clinical and genealogical analysis, video-EEG and MRI of the brain, and whole-exome sequencing. Results. The main result obtained in the study analysis of patients who underwent whole exome sequencing for the period of 2017-2023 was the detection rate of variants in genes associated with developmental and epileptic encephalopathy (21.7%; 71/331). Of these, 35/71 (49.3%) had pathogenic and probably pathogenic variants of the nucleotide sequence. Based on the results of whole exome sequencing patients were selected for the most effective targeted antiepileptic drugs. Conclusion. The use of whole-exome sequencing as a first-line molecular genetic test in patients with developmental and epileptic encephalopathy has been shown to be highly effective. Making an accurate genetic diagnosis is a fundamental background for precision therapy. Personalized medicine, that is, the attempt to personalize prevention, diagnosis, and treatment as much as possible according to the characteristics and needs of the patient, should be the main goal of clinical research and a new direction of modern medicine.


  • Open Access

    SPTAN1-associated developmental and epileptic encephalopathy

    by T. V. Kozhanova, S. S. Zhilina, T. I. Meshcheryakova, E. G. Lukyanova, E. S. Bolshakova, S. O. Ayvazyan, K. V. Osipova, P. A. Vlasov, A. I. Krapivkin, N. N. Zavadenko

    The article presents the clinical cases of 6 patients with epilepsy, psychomotor and speech developmental delay. The heterozygous variants of the nucleotide sequence in SPTAN1 gene were detected by whole exome sequencing. Mutations in SPTAN1 gene have been described in patients with developmental and epileptic encephalopathy 5 (ОMIM: 613477). The clinical history, electroencephalographic and magnetic resonance imaging data of our patients are similar in children with variants in SPTAN1 gene described previously. It was shown that variants in SPTAN1 gene located closer to the C-terminal region are associated with a more severe phenotype, whereas the variants near the N-region – with a milder course of the disease without structural brain anomalies. However, further research is necessary in the future to better understand genotype-phenotypic correlations in SPTAN1-associated encephalopathy.


  • Experience in organizing a ketogenic diet in preschool children

    by E. A. Pyr'YEva, A. I. Safronova, M. I. Timoshina, M. A. Toboleva, S. O. Aivazyan, K. V. Osipova, L. M. Sushko, E. O. Vlasova, E. G. Luk`yAnova

    Ketogenic diet (KD) refers to promising methods of treatment of epilepsy resistant to anticonvulsants. A clinical case of the use of KD in a child with drug resistant epilepsy (DRE) is presented. This clinical case demonstrates the effectiveness of KD in a child with DRE in the form of achieving 100% control over seizures and positive shifts in the psycho-motor development of the child and positive changes in the child’s psychomotor development while ensuring adequate physical health.


  • Open Access

    Pediatric Encephalopathy: Clinical, Biochemical and Cellular Insights into the Role of Gln52 of GNAO1 and GNAI1 for the Dominant Disease

    by Gonzalo P. Solis, Tatyana V. Kozhanova, Alexey Koval, Svetlana S. Zhilina, Tatyana I. Mescheryakova, Aleksandr A. Abramov, Evgeny V. Ishmuratov, Ekaterina S. Bolshakova, Karina V. Osipova, Sergey O. Ayvazyan, et al.

    Heterotrimeric G proteins are immediate transducers of G protein-coupled receptors—the biggest receptor family in metazoans—and play innumerate functions in health and disease. A set of de novo point mutations in GNAO1 and GNAI1, the genes encoding the α-subunits (Gαo and Gαi1, respectively) of the heterotrimeric G proteins, have been described to cause pediatric encephalopathies represented by epileptic seizures, movement disorders, developmental delay, intellectual disability, and signs of neurodegeneration. Among such mutations, the Gln52Pro substitutions have been previously identified in GNAO1 and GNAI1. Here, we describe the case of an infant with another mutation in the same site, Gln52Arg. The patient manifested epileptic and movement disorders and a developmental delay, at the onset of 1.5 weeks after birth. We have analyzed biochemical and cellular properties of the three types of dominant pathogenic mutants in the Gln52 position described so far: Gαo[Gln52Pro], Gαi1[Gln52Pro], and the novel Gαo[Gln52Arg]. At the biochemical level, the three mutant proteins are deficient in binding and hydrolyzing GTP, which is the fundamental function of the healthy G proteins. At the cellular level, the mutants are defective in the interaction with partner proteins recognizing either the GDP-loaded or the GTP-loaded forms of Gαo. Further, of the two intracellular sites of Gαo localization, plasma membrane and Golgi, the former is strongly reduced for the mutant proteins. We conclude that the point mutations at Gln52 inactivate the Gαo and Gαi1 proteins leading to aberrant intracellular localization and partner protein interactions. These features likely lie at the core of the molecular etiology of pediatric encephalopathies associated with the codon 52 mutations in GNAO1/GNAI1.


  • Open Access

    Clinical case of epilepsy, hearing loss and mental retardation syndrome associated with mutations in SPATA5 gene

    by T. V. Kozhanova, S. S. Zhilina, T. I. Meshcheryakova, E. G. Luk’yAnova, K. V. Osipova, S. O. Ayvazyan, A. G. Prityko, N. N. Zavadenko

    We present the clinical case of patient with epilepsy, developmental retardation and hearing loss. The whole exome sequencing allowed to reveal compound heterozygous variants of the nucleotide sequence in SPATA5 gene (c.1714+1G>A, c.1678G>A). Mutations in the SPATA5 gene have been described in patients with epilepsy, hearing loss and mental retardation syndrome (MIM 616577). Paired parents were carriers of one heterozygous gene variant. Such mutations lead to the development of epileptic disorders in 3% of cases, and should be considered in patients not only as a possible cause of neurodegenerative diseases, but also leading to pathology with clinical manifestations mimicking mitochondrial disease.


  • Open Access

    Helsmoortel-van der Aa syndrome syndrome in a patient with epilepsy, developmental delay, intellectual disability, and autism spectrum disorder

    by T. V. Kozhanova, S. S. Zhilina, T. I. Mescheryakova, E. G. Luk`yAnova, K. V. Osipova, S. O. Ayvazyan, A. G. Prityko

    Autism spectrum disorders (ASDs) are a group of complex disintegrative disorders of mental development, characterized by a lack of ability to social interaction, communication, stereotyped behavior, leading to social maladaptation. We present a rare clinical case of a delay in psychomotor and speech development, specific facial dysmorphia, impaired behavior, and a detected mutation in the ADNP gene. When conducting targeted exomic sequencing, we revealed a previously undescribed variant of the nucleotide sequence in the ADNP gene (p.Ala1017fs). Mutations in the ADNP gene in a heterozygous state were described for patients with Helsmoortel-van der Aa syndrome (OMIM: # 615873). Mutations in the ADNP gene are the genetic cause of ASD in 0.17% of cases. When interpreting the data of new generation sequencing (NGS) in patients with epileptic encephalopathy, ASD, and characteristic phenotype, it is advisable to take into account that the ADNP gene is one of the key genes responsible for embryonic neurodevelopment.